News
EWTX
44.31
-0.61%
-0.27
Edgewise Therapeutics Is Maintained at Neutral by Goldman Sachs
Dow Jones · 14h ago
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Benzinga · 14h ago
Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
TipRanks · 22h ago
Weekly Report: what happened at EWTX last week (0803-0807)?
Weekly Report · 1d ago
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
TipRanks · 5d ago
Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate
Benzinga · 5d ago
Edgewise Therapeutics GAAP EPS of -$0.53
Seeking Alpha · 5d ago
Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors
TipRanks · 6d ago
Weekly Report: what happened at EWTX last week (0727-0731)?
Weekly Report · 08/03 09:34
Edgewise Therapeutics Marks Key Milestone With EDG-7500 Phase 1 Completion
TipRanks · 07/31 16:30
Weekly Report: what happened at EWTX last week (0720-0724)?
Weekly Report · 07/27 09:36
Tracking Baker Brothers Portfolio: Q1 2026 Update
Seeking Alpha · 07/21 17:26
Edgewise Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 07/20 13:07
Edgewise Therapeutics Price Target Raised to $55.00/Share From $45.00 by Evercore ISI Group
Dow Jones · 07/20 13:07
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55
Benzinga · 07/20 12:57
Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI
TipRanks · 07/20 12:50
Weekly Report: what happened at EWTX last week (0713-0717)?
Weekly Report · 07/20 09:34
Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier
TipRanks · 07/13 17:28
Edgewise Therapeutics completes sale of sevasemten for up to $2.65B
TipRanks · 07/13 12:40
Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4
TipRanks · 07/13 12:40
More
Webull provides a variety of real-time EWTX stock news. You can receive the latest news about Edgewise Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About EWTX
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).